ArticleInternational urogynecology journal2026
Multicentric Preliminary Experience and Clinical Outcomes of Female Urethral Dilation Using a Paclitaxel-Coated Balloon.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisTo evaluate the feasibility, safety, and preliminary clinical outcomes of paclitaxel-coated balloon (Optilume®) dilation in women with urethral stricture disease, a condition with limited minimally invasive treatment options.
methodsMulticenter, retrospective case series, including nine consecutive female patients treated with Optilume® between May 2023 and November 2025. Clinical characteristics, uroflowmetry, post-void residual (PVR), and patient-reported outcomes were collected. A uroflowmetric response was defined as a ≥ 50% increase in maximum flow rate (Qmax). Symptomatic improvement was assessed using the Patient Global Impression of Improvement (PGI-I) scale. Pre- and postoperative Qmax and PVR were compared using the Wilcoxon signed-rank test.
resultsNine women were included (mean age 63.2 years; SD 15.6). Median Qmax improved from 8.6 to 13.6 mL/s (p = 0.012). Median PVR decreased from 56 to 0 mL (p = 0.043). A uroflowmetric response was achieved in 66.7% (6/9). All procedures were outpatient, with no intra- or postoperative complications and no de novo stress urinary incontinence. One patient (11.1%) required reintervention for recurrence at 5 months, successfully managed with internal urethrotomy. All patients reported improvement on PGI-I: 66.7% (6/9) "very much better" and 33.3% (3/9) "better." At short-term follow-up (mean 11 months; variable), 88.9% (8/9) remained free of reintervention.
conclusionsIn this small, retrospective multicenter cohort, paclitaxel-coated balloon dilation appeared feasible and was not associated with major procedure-related complications in the short term, with encouraging functional and patient-reported improvements. These findings are preliminary and hypothesis-generating; prospective controlled studies with larger samples and longer, standardized follow-up are needed to better define effectiveness and durability.
Indexed as
Identifiers
42159728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.